Navigation Links
Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
Date:5/8/2008

stry revenues rose 8.3% to $130.5 billion

-- Neuropharmaceuticals recorded revenues of $109 billion and 8% annual

growth

-- Neurodevices recorded revenues of $5.5 billion and 22% annual growth

-- Neurodiagnostics recorded revenues of $16 billion and 6% annual growth

"The neurotechnology industry made substantial gains in 2007, which has continued into 2008," said Casey Lynch, Managing Director of NeuroInsights. "Commercial neuroscience represents one of the fastest-growing and critically needed sectors of the healthcare industry. In 2007, this was underscored in the launch of several important industry initiatives, including the creation of the NASDAQ NeuroInsights Neurotech Index in September."

Specific milestones from the report were presented during NeuroInsights' annual Neurotech Industry Investing and Partnering Conference, hosted in partnership with the Neurotechnology Industry Organization. This conference, being held at the Westin Copley Place in Boston today and tomorrow, is the premier global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

The Neurotechnology Industry 2008 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is now available for purchase in book or digital format at http://www.neuroinsights.com/marketreports/marketreport2008.html

About NeuroInsights

NeuroInsights is the world's leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment
'/>"/>

SOURCE NeuroInsights
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Neurotechnology Industry Organization Unveils Top 10 Neuroscience Trends of 2007
2. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
3. Facet Solutions, Inc. Appoints Industry Veteran to Board of Directors
4. Anthem Blue Cross and Blue Shield in Connecticut Introduces Industrys First Electronic Tool to Help Members Search In-Network Doctors and Hospitals; Transparency Tool to Enable Searches Via Web-Enabled Cell Phones or Hand-Held Devices
5. Anthem Blue Cross and Blue Shield Introduces Industrys Most Comprehensive Transparency Initiative to Wisconsin
6. Pharma Industry Group Favors Obama as Next President
7. Key Industry and Government Officials to Address Medical Technology Executives
8. China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention
9. The National Association of Specialty Health Organizations to Recognize Excellence in Technology Education With Industry Award
10. Siemens Healthcare Executives Recognized With New Industry Leadership Positions
11. Entertainment Industry Foundation Revlon Run/Walk for Women Celebrates 11 Years in New York City on Saturday, May 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Veinwave Eliminates Spider Veins and Telangiectasia , ... (PRWEB) December 10, 2009 ... and telangiectasia – those unsightly clusters of red, blue or ... In fact, for Western populations like the US, it’s been estimated that ... , , , , ,Although the Veinwave has been ...
(Date:12/15/2009)... Ill. A study in the Dec. 15 ... Medicine indicates that significant associations exist between ... regurgitation and headaches in young school-aged children. ... parent-reported insomnia was 3.3 times more likely in ... likely in children with headaches. Nineteen percent ...
(Date:12/14/2009)... particles carry oxygen, drugs, and more… , ... ... Santa Barbara, in collaboration with scientists at University of Michigan, ... key functions of natural red blood cells, including softness, flexibility, ... , ,The primary function of natural red blood cells is ...
(Date:12/14/2009)... 14 Americold Realty Trust ("Americold") announced today ... S-11 with the U.S. Securities and Exchange Commission (the ... its common shares. The number of shares to be ... not yet been determined. The common shares to be ... by Americold. ,, The joint book-running managers of ...
(Date:12/14/2009)... WASHINGTON, Dec. 14 The National Organization for ... an immediate end to lifetime and annual health insurance ... Politico, a newspaper distributed widely on Capitol Hill, ... loopholes that would allow caps to continue for most ... "NORD supports health care reform and welcomes the promises ...
Breaking Medicine News(10 mins):Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2
... prisoners has failed to solve the crisis that is ... the BMA today. ,The 19th July marks ... introduction of emergency measures designed to alleviate the overcrowding ... of the Government strategy was an early release programme ...
... a long-standing belief that male circumcision can reduce HIV ... AIDS conference will be told next week . ... Society (IAS) conference to be held in Sydney from ... major development in HIV prevention. ,"We always ...
... a product recall in US without a Chinese link. Following ... a Georgia facility are being withdrawn in USA. ... canned foods in nearly four decades. ,Health officials ... leading brands like Castleberry's, Kroger and Austex . ...
... rise in the number of Australian HIV cases in the ... risky sexual behaviour in men having sex with men, and ... emerge, according to research published online for the Medical Journal ... Professor of Epidemiology at the National Centre in HIV Epidemiology ...
... Some chain-smokers are reluctant or incapable of quitting smoking, but ... they smoke each day . ,However, after studying ... very little attention has been given to this alternative of ... effort in therapies aimed at smokers has been at helping ...
... non-pyrethroid insecticide, propoxur, and a repellent, N,N-diethyl toluamide ... synergy against mosquitoes responsible for malaria transmission to ... had proved to be much more effective than ... nets soaked with this mixture had a lethal ...
Other Medicine News:Health News:Prison Healthcare Continues to Fail Despite Emergency Measures, Warns BMA 2Health News:Male Circumcision can Cut HIV Infection, Studies Show 2Health News:Chilly Sauce Linked to Botulism, Forcing Recall in US 2Health News:Chilly Sauce Linked to Botulism, Forcing Recall in US 3Health News:HIV Cases Increasing In Australia 2Health News:Chain Smokers Prepared to Lessen Their Daily Cigs Rather Than Quitting 2Health News:Insecticide and Repellent Combo Effective in Eliminating Malarial Mosquitoes 2
(Date:12/14/2009)... Calif., Dec. 14 The Roberts ... today released the analysis of social responsibility ... world-wide. The report contains a compilation of ... environmental and social reporting of the companies. ... and performance for both environmental and social ...
(Date:12/14/2009)... According to Millennium Research Group ... market intelligence, Japan,s complex regulatory environment and ... significant lag in peripheral vascular stenting device ... developed nations. MRG,s new Japanese ... report finds, however, that recent indication-specific device ...
(Date:12/14/2009)... The U.S. Food and Drug Administration (FDA) ... Suspension for the treatment of schizophrenia in adults, ... ) announced today. ZYPREXA RELPREVV, a long-acting intramuscular ... to four weeks. ,, Different from both oral ... allow for stable concentrations of the active drug ...
Breaking Medicine Technology:New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 3Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014 2Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8FamilyLife Supports Military Marriages in Atlanta 62459 1FamilyLife Supports Military Marriages in Atlanta 62459 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 1Ministerial Roundtable Discusses Future of Medical Tourism 62455 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 3Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 1Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 2Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 3Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 4Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 5
... England, December 8 , ... Completed Price and,Reimbursement Approval for Tetrabenazine in H1 2009 ... Distribution Rights Granted in Finland (MediFront) and Taiwan,(Giddi Pharma); ... Cambridge Laboratories Limited ...
... 7 Millennium: The Takeda Oncology,Company today ... randomized, multi-center,Company-sponsored Phase I/II study of VELCADE, ... previously untreated multiple,myeloma (MM). The preliminary analysis ... of four drugs was generally well tolerated ...
Other Medicine Technology:Cambridge Laboratories Announces Approval of Tetrabenazine in Spain 2Cambridge Laboratories Announces Approval of Tetrabenazine in Spain 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6
... monoclonal antibody based colorimetric test intended ... gonorrhoeae. The test requires less than ... heating or pretreatment. The test does ... cultures. GonoGen&trade II eliminates agglutination, guesswork, ...
... a monoclonal antibody based coagglutination ... identification of Neisseria gonorrhoeae. The ... viable or fresh cultures. After ... minute rotation, a positive reaction ...
Rapid Test Kit...
... a novel device for the growth ... and Neisseria meningitidis. This product ... is easily transportable as a self-contained ... and examine the growth of organisms ...
Medicine Products: